ArticleFrontiers in molecular biosciences2026
Adenosine metabolism as an endogenous protective mechanism in response to upstream ischemic injury.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Following ischemic stroke (IS), endogenous protective mechanisms are activated to mitigate brain injury. Adenosine (ADO), a key endogenous immunomodulator, is implicated in this response, yet the precise regulatory pathways linking upstream ischemic injury to ADO-mediated protection remain incompletely elucidated. Methods: We integrated single-cell RNA sequencing (scRNA-seq) data (GSE174574) and bulk RNA-seq data (GSE140275) from IS models. After preprocessing and t-SNE-based clustering, we conducted analyses of cell communication and differential expression. Differentially expressed genes were intersected with ADO metabolism-related genes from the GeneCards database to identify candidate regulators. The roles of these candidates in modulating ADO metabolism, oxidative stress, and apoptosis were functionally validated Results: Unsupervised clustering of scRNA-seq data identified 14 cell types, with microglia displaying extensive intercellular communication, particularly via the CCL and TNF signaling pathways. Cross-database analysis identified four candidate molecules: HMBS, UCP2, POR, and TNF. These were positively correlated with pro-ADO metabolic genes in middle cerebral artery occlusion (MCAO) models and were upregulated in LPS-stimulated BV2 cells, coinciding with increased inflammation, oxidative stress, and ADO levels. Silencing HMBS or POR reversed these effects. Exogenous ADO reduced oxidative stress and apoptosis in BV2 cells and promoted M2 microglia polarization. Conclusion: Our findings suggest that ischemic injury upregulates specific molecules (HMBS, UCP2, POR, and TNF) potentially associated with ADO metabolism, which may, in turn, alleviate oxidative stress and apoptosis while favoring anti-inflammatory microglial polarization. This supports the hypothesis that enhanced adenosine metabolism represents a potential endogenous protective mechanism activated in response to upstream ischemic insult. HMBS or POR silencing upregulated adenosine deaminase/adenosine kinase (ADA/ADK) and downregulated SLC29A1/A2 in LPS-stimulated BV2 cells. The protective effects of ADO were abolished by A
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.